<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300468</url>
  </required_header>
  <id_info>
    <org_study_id>CDKO-125a-001</org_study_id>
    <nct_id>NCT01300468</nct_id>
  </id_info>
  <brief_title>Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Study of Oral PHA-848125AC Given Daily For 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days A Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients With Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerviano Medical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerviano Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, multi center, Phase I study was to determine the safety&#xD;
      profile of the oral compound PHA-848125AC administered according to two different schedules&#xD;
      of administrations to advanced/metastatic solid tumor patients. Objectives of the study were&#xD;
      to determine the maximum tolerated dose and the dose that can be recommended for Phase II&#xD;
      investigations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of Dose Limiting Toxicities and Maximum Tolerated Dose</measure>
    <time_frame>First cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events (based on CTCAE version 3.0)</measure>
    <time_frame>All cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics: plasma concentrations at different times after dosing and related assessment of conventional pharmacokinetic parameters</measure>
    <time_frame>First 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Solid Tumour</condition>
  <arm_group>
    <arm_group_label>Dose-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHA-848125AC</intervention_name>
    <arm_group_label>Dose-escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed, written IRB-approved Informed Consent&#xD;
&#xD;
          -  Histologically or cytologically confirmed relapsed or refractory solid tumors for&#xD;
             which no standard therapy exists&#xD;
&#xD;
          -  ECOG (WHO) performance status 0-1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Age &gt;=18 years&#xD;
&#xD;
          -  A negative pregnancy test (if female in reproductive years)&#xD;
&#xD;
          -  Acceptable liver and renal function&#xD;
&#xD;
          -  Acceptable hematologic status&#xD;
&#xD;
          -  10. Previous cancer therapy is allowed with the exclusion of experimental CDK2&#xD;
             inhibitors. Treatment with radiation therapy, surgery, chemotherapy, or&#xD;
             investigational therapy must be completed within one month prior to study entry&#xD;
&#xD;
          -  Use of effective contraceptive methods if men and women of child producing potential&#xD;
&#xD;
          -  Capability to swallow capsules intact&#xD;
&#xD;
          -  Grade &lt;=1 retinopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the past 6 months: myocardial infarction, unstable angina, coronary/peripheral&#xD;
             artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or&#xD;
             transient ischemic attack, pulmonary embolism, deep vein thrombosis&#xD;
&#xD;
          -  Known brain metastases&#xD;
&#xD;
          -  Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Unwillingness or inability to comply with procedures required in this protocol&#xD;
&#xD;
          -  Known infection with HIV, active hepatitis B or hepatitis C&#xD;
&#xD;
          -  Diabetes mellitus uncontrolled, or with clinical evidence of diabetic retinopathy,&#xD;
             severe peripheral vascular disease or diabetic ulcers&#xD;
&#xD;
          -  Current enrollment in another clinical trial&#xD;
&#xD;
          -  Patients who have exhibited allergic reactions to a similar structural compound,&#xD;
             biological agent, or formulation (lactose intolerance)&#xD;
&#xD;
          -  Previous history or current presence of neurological disorders, including epilepsy&#xD;
             (although controlled by anticonvulsant therapy), Parkinson's disease, multiple&#xD;
             sclerosis, stroke and cerebellar injury&#xD;
&#xD;
          -  Gastrointestinal disease (e.g. Crohn's disease, ulcerative colitis, or short gut&#xD;
             syndrome) that would impact on drug absorption&#xD;
&#xD;
          -  Chronic/intensive use of antacid or H2 receptor antagonists&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or may&#xD;
             interfere with the interpretation of study results and, in the judgment of the&#xD;
             investigator, would make the patient inappropriate for entry into this study or could&#xD;
             compromise protocol objectives in the opinion of the investigator and/or the sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Von Hoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scottsdale Clinical Research Institute, Scottsdale AZ, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Hidalgo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Johns Hopkins University, Baltimore MD, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Laheru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Johns Hopkins University, Baltimore MD, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Clinical Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltiomore</city>
        <state>Maryland</state>
        <zip>21212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Research Head</name_title>
    <organization>Nerviano Medical Sciences</organization>
  </responsible_party>
  <keyword>advanced/metastatic solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

